Loading…
Employees: 2,870
Size Youcare Pharmaceutical (688658.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $776M, the 2841st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.50 on 6 Nov 2026.
Performance Over six months the shares fell 41.3%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 7.3% over the last twelve months (peer median +3.9%); the operating margin is -13.2% (peer median 8.8%).
Valuation It trades at 28.8× forward earnings against a peer median of 17.8× (3rd most expensive of 8).
Capital Return on invested capital runs 11.4 points below its cost of capital (7.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.36B | CN¥2.42B | CN¥3.75B | CN¥4.16B | CN¥4.50B |
| Revenue growth | — | -35% | -10% | -8% | — |
| Gross profit | CN¥1.37B | CN¥1.11B | CN¥2.06B | CN¥2.52B | CN¥2.83B |
| EBITDA | n/a | -CN¥25.3M | CN¥385M | CN¥379M | CN¥406M |
| Net income | -CN¥318M | -CN¥262M | CN¥124M | CN¥185M | CN¥335M |
| Free cash flow | -CN¥8.08M | CN¥209M | CN¥79.9M | CN¥288M | -CN¥668M |
| Capital expenditure | CN¥104M | CN¥135M | CN¥359M | CN¥497M | CN¥548M |
| Total debt | CN¥861M | CN¥738M | CN¥915M | CN¥678M | CN¥558M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688658.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | -0.4% | 5th lowest of 20 |
| 6-month return | -41.3% | -9.5% | lowest of 20 |
| Distance from 52-week high | -64.2% | -32.1% | lowest of 20 |
| Revenue growth (TTM) | -7.3% | +3.9% | 5th lowest of 19 |
| Operating margin | -13.2% | 8.8% | 4th lowest of 19 |
| Forward P/E | 28.8× | 17.8× | 3rd most expensive of 8 |
| ROIC minus cost of capital | -11.4 pp | +0.2 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 28.8× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 12.4× | -6.3% | +10.6% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 11.9× | 11.5% | +11.3% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | n/a | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 3.4× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 17.8× | -1.1% | +26.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | n/a | 0.2% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | n/a | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | n/a | 4.9% | +5.3% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 19.9× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 76.4× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | n/a | 18.2% | +2.1% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | n/a | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | n/a | -3.0% | -0.8% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 123.9× | 33.8% | +19.8% |